|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Giornelli GH: Management of relapsed
ovarian cancer: A review. Springerplus. 5:11972016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bast RC Jr, Hennessy B and Mills GB: The
biology of ovarian cancer: New opportunities for translation. Nat
Rev Cancer. 9:415–428. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dong A, Lu Y and Lu B: Genomic/epigenomic
alterations in ovarian carcinoma: Translational insight into
clinical practice. J Cancer. 7:1441–1451. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Grunewald T and Ledermann JA: Targeted
therapies for ovarian cancer. Best Pract Res Clin Obstet Gynaecol.
41:139–152. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Smith HJ, Straughn JM, Buchsbaum DJ and
Arend RC: Epigenetic therapy for the treatment of epithelial
ovarian cancer: A clinical review. Gynecol Oncol Rep. 20:81–86.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Eckschlager T, Plch J, Stiborova M and
Hrabeta J: Histone deacety-lase inhibitors as anticancer drugs. Int
J Mol Sci. 18:E14142017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Manal M, Chandrasekar MJ, Gomathi Priya J
and Nanjan MJ: Inhibitors of histone deacetylase as antitumor
agents: A critical review. Bioorg Chem. 67:18–42. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mottamal M, Zheng S, Huang TL and Wang G:
Histone deacetylase inhibitors in clinical studies as templates for
new anticancer agents. Molecules. 20:3898–3941. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ropero S and Esteller M: The role of
histone deacetylases (HDACs) in human cancer. Mol Oncol. 1:19–25.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Budman DR, Tai J, Calabro A and John V:
The histone deacetylase inhibitor panobinostat demonstrates marked
synergy with conventional chemotherapeutic agents in human ovarian
cancer cell lines. Invest New Drugs. 29:1224–1229. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chao H, Wang L, Hao J, Ni J, Chang L,
Graham PH, Kearsley JH and Li Y: Low dose histone deacetylase
inhibitor, LBH589, potentiates anticancer effect of docetaxel in
epithelial ovarian cancer via PI3K/Akt pathway in vitro. Cancer
Lett. 329:17–26. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cooper AL, Greenberg VL, Lancaster PS, van
Nagell JR Jr, Zimmer SG and Modesitt SC: In vitro and in vivo
histone deacetylase inhibitor therapy with suberoylanilide
hydroxamic acid (SAHA) and paclitaxel in ovarian cancer. Gynecol
Oncol. 104:596–601. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Konstantinopoulos PA, Wilson AJ, Saskowski
J, Wass E and Khabele D: Suberoylanilide hydroxamic acid (SAHA)
enhances olaparib activity by targeting homologous recombination
DNA repair in ovarian cancer. Gynecol Oncol. 133:599–606. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cassier PA, Floquet A, Penel N, Derbel O,
Bui N'guyen B, Guastalla JP, Pissaloux D, Treilleux I, Saba CE,
Blay JY, et al: The histone deacetylase inhibitor panobinostat is
active in patients with advanced pretreated ovarian sex-cord
tumors. Ann Oncol. 25:1074–1075. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Matulonis U, Berlin S, Lee H, Whalen C,
Obermayer E, Penson R, Liu J, Campos S, Krasner C and Horowitz N:
Phase I study of combination of vorinostat, carboplatin, and
gemcitabine in women with recurrent, platinum-sensitive epithelial
ovarian, fallopian tube, or peritoneal cancer. Cancer Chemother
Pharmacol. 76:417–423. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Modesitt SC, Sill M, Hoffman JS and Bender
DP; Gynecologic Oncology Group, : A phase II study of vorinostat in
the treatment of persistent or recurrent epithelial ovarian or
primary peritoneal carcinoma: A Gynecologic Oncology Group study.
Gynecol Oncol. 109:182–186. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Giacinti L, Giacinti C, Gabellini C,
Rizzuto E, Lopez M and Giordano A: Scriptaid effects on breast
cancer cell lines. J Cell Physiol. 227:3426–3433. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Janaki Ramaiah M, Naushad SM, Lavanya A,
Srinivas C, Anjana Devi T, Sampathkumar S, Dharan DB and Bhadra MP:
Scriptaid cause histone deacetylase inhibition and cell cycle
arrest in HeLa cancer cells: A study on structural and functional
aspects. Gene. 627:379–386. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sharma V, Koul N, Joseph C, Dixit D, Ghosh
S and Sen E: HDAC inhibitor, scriptaid, induces glioma cell
apoptosis through JNK activation and inhibits telomerase activity.
J Cell Mol Med. 14:2151–2161. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Takai N, Ueda T, Nishida M, Nasu K and
Narahara H: A novel histone deacetylase inhibitor, Scriptaid,
induces growth inhibition, cell cycle arrest and apoptosis in human
endometrial cancer and ovarian cancer cells. Int J Mol Med.
17:323–329. 2006.PubMed/NCBI
|
|
22
|
Berghauser Pont LM, Kleijn A, Kloezeman
JJ, van den Bossche W, Kaufmann JK, de Vrij J, Leenstra S, Dirven
CM and Lamfers ML: The HDAC inhibitors scriptaid and LBH589
combined with the oncolytic virus Delta24-RGD exert enhanced
anti-tumor efficacy in patient-derived glioblastoma cells. PLoS
One. 10:e01270582015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Manasanch EE and Orlowski RZ: Proteasome
inhibitors in cancer therapy. Nat Rev Clin Oncol. 14:417–433. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Minami J, Suzuki R, Mazitschek R, Gorgun
G, Ghosh B, Cirstea D, Hu Y, Mimura N, Ohguchi H, Cottini F, et al:
Histone deacetylase 3 as a novel therapeutic target in multiple
myeloma. Leukemia. 28:680–689. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dimopoulos M, Siegel DS, Lonial S, Qi J,
Hajek R, Facon T, Rosinol L, Williams C, Blacklock H, Goldschmidt
H, et al: Vorinostat or placebo in combination with bortezomib in
patients with multiple myeloma (VANTAGE 088): A multicentre,
randomised, double-blind study. Lancet Oncol. 14:1129–1140. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Karthik S, Sankar R, Varunkumar K and
Ravikumar V: Romidepsin induces cell cycle arrest, apoptosis,
histone hyperacetylation and reduces matrix metalloproteinases 2
and 9 expression in bortezomib sensitized non-small cell lung
cancer cells. Biomed Pharmacother. 68:327–334. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ma YY, Lin H, Moh JS, Chen KD, Wang IW, Ou
YC, You YS and Lung CC: Low-dose LBH589 increases the sensitivity
of cisplatin to cisplatin-resistant ovarian cancer cells. Taiwan J
Obstet Gynecol. 50:165–171. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ong PS, Wang XQ, Lin HS, Chan SY and Ho
PC: Synergistic effects of suberoylanilide hydroxamic acid combined
with cisplatin causing cell cycle arrest independent apoptosis in
platinum-resistant ovarian cancer cells. Int J Oncol. 40:1705–1713.
2012.PubMed/NCBI
|
|
29
|
Pradhan S, Mahajan D, Kaur P, Pandey N,
Sharma C and Srivastava T: Scriptaid overcomes hypoxia-induced
cisplatin resistance in both wild-type and mutant p53 lung cancer
cells. Oncotarget. 7:71841–71855. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chou TC and Talalay P: Quantitative
analysis of dose-effect relationships: The combined effects of
multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chou TC: Theoretical basis, experimental
design, and computerized simulation of synergism and antagonism in
drug combination studies. Pharmacol Rev. 58:621–681. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Spratlin JL, Pitts TM, Kulikowski GN,
Morelli MP, Tentler JJ, Serkova NJ and Eckhardt SG: Synergistic
activity of histone deacetylase and proteasome inhibition against
pancreatic and hepatocellular cancer cell lines. Anticancer Res.
31:1093–1103. 2011.PubMed/NCBI
|
|
33
|
Zhang H, Dong L, Chen Q, Kong L, Meng B,
Wang H, Fu K, Wang X, Pan-Hammarström Q, Wang P, et al: Synergistic
antitumor effect of histone deacetylase inhibitor and Doxorubicin
in peripheral T-cell lymphoma. Leuk Res. 56:29–35. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jessmon P, Boulanger T, Zhou W and
Patwardhan P: Epidemiology and treatment patterns of epithelial
ovarian cancer. Expert Rev Anticancer Ther. 17:427–437. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Meehan RS and Chen AP: New treatment
option for ovarian cancer: PARP inhibitors. Gynecol Oncol Res
Pract. 3:32016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pitts TM, Morrow M, Kaufman SA, Tentler JJ
and Eckhardt SG: Vorinostat and bortezomib exert synergistic
antiproliferative and proapoptotic effects in colon cancer cell
models. Mol Cancer Ther. 8:342–349. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Modesitt SC and Parsons SJ: In vitro and
in vivo histone deacetylase inhibitor therapy with vorinostat and
paclitaxel in ovarian cancer models: Does timing matter? Gynecol
Oncol. 119:351–357. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Grassadonia A, Cioffi P, Simiele F, Iezzi
L, Zilli M and Natoli C: Role of hydroxamate-based histone
deacetylase inhibitors (Hb-HDACIs) in the treatment of solid
malignancies. Cancers (Basel). 5:919–942. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Su GH, Sohn TA, Ryu B and Kern SE: A novel
histone deacetylase inhibitor identified by high-throughput
transcriptional screening of a compound library. Cancer Res.
60:3137–3142. 2000.PubMed/NCBI
|
|
40
|
Keen JC, Yan L, Mack KM, Pettit C, Smith
D, Sharma D and Davidson NE: A novel histone deacetylase inhibitor,
scriptaid, enhances expression of functional estrogen receptor
alpha (ER) in ER negative human breast cancer cells in combination
with 5-aza 2′-deoxycytidine. Breast Cancer Res Treat. 81:177–186.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Abaza MS, Bahman AM, Al-Attiyah RJ and
Kollamparambil AM: Synergistic induction of apoptosis and
chemosensitization of human colorectal cancer cells by histone
deacetylase inhibitor, scriptaid, and proteasome inhibitors:
Potential mechanisms of action. Tumour Biol. 33:1951–1972. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sato A and Asano T, Ito K, Sumitomo M and
Asano T: Suberoylanilide hydroxamic acid (SAHA) combined with
bortezomib inhibits renal cancer growth by enhancing histone
acetylation and protein ubiquitination synergistically. BJU Int.
109:1258–1268. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sato A and Asano T, Ito K and Asano T:
Vorinostat and bortezomib synergistically cause ubiquitinated
protein accumulation in prostate cancer cells. J Urol.
188:2410–2418. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chhabra S: Novel proteasome inhibitors and
histone deacetylase inhibitors: Progress in myeloma therapeutics.
Pharmaceuticals (Basel). 10:402017. View Article : Google Scholar :
|
|
45
|
Tan D, Diong CP, Loh Y and Goh YT: Histone
deacetylase (HDAC) inhibitors when combined with a proteasome
inhibitor are safe and effective in patients with extranodal
natural killer/T-cell lymphoma (ENKTL). Ann Oncol. 27:1811–1812.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Jin X, Fang Y, Hu Y, Chen J, Liu W, Chen
G, Gong M, Wu P, Zhu T, Wang S, et al: Synergistic activity of the
histone deacetylase inhibitor trichostatin A and the proteasome
inhibitor PS-341 against taxane-resistant ovarian cancer cell
lines. Oncol Lett. 13:4619–4626. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Jandial DA, Brady WE, Howell SB, Lankes
HA, Schilder RJ, Beumer JH, Christner SM, Strychor S, Powell MA,
Hagemann AR, et al: A phase I pharmacokinetic study of
intraperitoneal bortezomib and carboplatin in patients with
persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic
Oncology Group study. Gynecol Oncol. 145:236–242. 2017. View Article : Google Scholar : PubMed/NCBI
|
